NEUREN PHARMACEUTICALS LIMITED - News & Media

Market Cap $1.730B Add to my watchlist

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

No News & Media currently available.

(20min delay)
Last $16.71		Change -0.590(3.41%)		Mkt cap ! $1.730B

Open	High	Low	Value	Volume
$17.50	$17.55	$16.57	$10.01M	594.0K

Buyers (Bids)

No.	Vol.	Price($)
1	2158	$16.71

Sellers (Offers)

Price($)	Vol.	No.
$16.72	4268	2

View Market Depth

No.	Vol.	Price($)
2	14520	1.150
1	2000	1.120
4	19428	1.100
2	3170	1.095
2	3800	1.090

Price($)	Vol.	No.
1.180	2720	1
1.185	50000	1
1.190	24200	2
1.200	5500	2
1.210	9800	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)


Last $16.77		Change -0.590 ( 3.86 %)
Open	High	Low	Volume
$17.48	$17.55	$16.57	123594
Last updated 15.59pm 15/11/2024 ?

NEU (ASX) Chart